Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
about
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone healthBone disease in HIV infection.Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudyBone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142.Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review.Moving from viral suppression to comprehensive patient-centered care: the high prevalence of comorbid conditions and health risk factors in HIV-1-infected patients in Australia.
P2860
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
@ast
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
@en
type
label
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
@ast
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
@en
prefLabel
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
@ast
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
@en
P2860
P1476
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.
@en
P2093
Elizabeth Shane
Michael T Yin
P2860
P304
P356
10.1097/MED.0B013E3280109B6C
P577
2006-12-01T00:00:00Z